by Eliza Folsom
Results from a recent Yale Cancer Center Phase II trial studying ixabepilone and bevacizumab vs ixabepilone alone in platinum resistant ovarian cancer patients have led to the combination added as a Category 2B recommended regimen in Ovarian Cancer (Version 1.2023) of the National Comprehensive Cancer Network (NCCN) Guidelines®.
The results of the study, which was authored by Alessandro Santin, MD, Professor of Obstetrics, Gynecology & Reproductive Sciences, and Co-Chief, Section of Gynecologic Oncology, and Elena Ratner, MD, Professor of Obstetrics, Gynecology & Reproductive Sciences, and Co-Chief, Section of Gynecologic Oncology, were published in the British Journal of Cancer and represent ‘a well-tolerated regimen with encouraging activity.’
“The new standard of care for platinum resistant ovarian cancer is great news as another treatment option is now available for patients with platinum-resistant disease,” said Dr. Santin. “I would like to thank all co-authors of this paper as well as the gynecologic oncology personnel in our Clinical Trials Office that worked so hard to enroll patients and complete the Yale Investigator-Initiated Trial.”
NCCN Guidelines® are the recognized standard for clinical direction and policy in cancer care. The latest updates for ovarian cancer were released in December, 2022.
This article was published by Yale School of Medicine.